Keep up to date with our fundraising progress, new initiatives, relevant news articles and updates from the team at The Rare Initiative.
A message from our founder.
Silmitasertib granted Orphan Drug Designation
The first potent and selective FGFR2 inhibitor.
Erika Tarantal interviews Jacqui
A revolution in cancer detection and treatment.
MGH discovers link between two FGFR inhibitors.
Ivosidenib approved for use in CCA.
An IDH1 breakthrough for CCA.
Featuring Dr Lipika Goyal.
Join our fundraising movement.
Future projections of cancer burden.
Breakthrough Designation for Futibatinib.
A moment of opportunity.
Follow us @therareinitiative.
Start your own WigOut fundraiser.
Click here to visit our page.
See our live fundraising total.
Henri & Belinda Termeer Center for Targeted Therapies Mass General Cancer Center 55 Fruit Street, Boston MA
E: [email protected]
